EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Refined pharmacovigilance assessment of immune checkpoint inhibitors-related bullous pemphigoid: a multi-methodological approach utilizing FAERS database

Yan Wang, Liu-Yi-Yi Yang, Ya-Gang Zuo

Journal of Pharmacy & Pharmaceutical Sciences · 2026

DOI: 10.3389/jpps.2025.15597 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy & Pharmaceutical Sciences, 2026. Verfasst von Yan Wang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, PUMC Hospital, CAMS and PUMC, National Clinical Research Center …. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Pharmacovigilance, Immune Checkpoint Inhibitors. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To evaluate the potential risk of bullous pemphigoid (BP) in patients treated with immune checkpoint inhibitors (ICIs) and to characterize ICI-related BP (irBP) using the United States Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Methods

The present study conducted a disproportionality analysis leveraging FAERS database, spanning the first quarter (Q1) of 2004–2025 Q1. To ensure robust signal detection, we employed a quadruple analytical approach incorporating: (1) reporting odds ratio (ROR), (2) proportional reporting ratio, (3) Bayesian confidence propagation neural network, and (4) multi-item gamma Poisson shrinker algorithms. These methodologies were systematically applied to assess the potential risk of BP in patients treated with ICIs. Furthermore, temporal characteristics of adverse event emergence were quantitatively assessed to delineate the time-to-onset patterns.

Results

There are 850 irBP cases identified, comprising reports associated with the following agents: nivolumab (n = 530), pembrolizumab (n = 180), ipilimumab (n = 44), atezolizumab (n = 40), cemiplimab (n = 24), durvalumab (n = 19), tislelizumab (n = 10), and avelumab (n = 3). Affected patients were predominantly males (67.8%) and over 60 years of age (70.1%). All eight ICIs showed positive disproportionality signals, with ROR values ranked descendingly as: cemiplimab > nivolumab > tislelizumab > pembrolizumab > ipilimumab > durvalumab > atezolizumab > avelumab. The median time of irBP onset was 165.2 (IQR: 56–410) days.

Conclusion

The study establishes a significant link between ICIs and BP. All ICIs increase BP risk. CTLA-4 inhibitors exhibited the most marked early risk concentration, highlighting the importance of early dermatologic evaluation after initiating CTLA-4 blockade.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousPharmacovigilanceImmune Checkpoint InhibitorsHumansAdverse Drug Reaction Reporting SystemsFemaleDatabases, FactualMaleUnited StatesAgedUnited States Food and Drug AdministrationMiddle AgedAged, 80 and over

Stichwörter der Autor:innen

FAERSadverse drug eventsbullous pemphigoidimmune checkpoint inhibitorspharmacovigilance

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Dermatology, State Key Laboratory of Complex Severe and Rare Diseases, PUMC Hospital, CAMS and PUMC, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China.

Zitieren

APA

Wang, Y., Yang, L. Y., & Zuo, Y. G. (2026). Refined pharmacovigilance assessment of immune checkpoint inhibitors-related bullous pemphigoid: a multi-methodological approach utilizing FAERS database. Journal of Pharmacy & Pharmaceutical Sciences. https://doi.org/10.3389/jpps.2025.15597

Vancouver

Wang Y, Yang LY, Zuo YG. Refined pharmacovigilance assessment of immune checkpoint inhibitors-related bullous pemphigoid: a multi-methodological approach utilizing FAERS database. Journal of Pharmacy & Pharmaceutical Sciences. 2026. doi:10.3389/jpps.2025.15597

BibTeX
@article{Wang2026,
  author = {Wang, Yan and Yang, Liu-Yi-Yi and Zuo, Ya-Gang},
  title = {Refined pharmacovigilance assessment of immune checkpoint inhibitors-related bullous pemphigoid: a multi-methodological approach utilizing FAERS database},
  journal = {Journal of Pharmacy & Pharmaceutical Sciences},
  year = {2026},
  doi = {10.3389/jpps.2025.15597}
}
Kostenlos starten →